ArticleCell reports2023
Vaginal epithelial dysfunction is mediated by the microbiome, metabolome, and mTOR signaling.
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- Persistence of Bacterial Dysbiosis, Cervicovaginal Human Papillomaviruses, and Inflammation in Women Living With HIV-1 After a Year of Antiretroviral Therapy.The Journal of infectious diseases · 2026Observational
- Poloxamer/HPMC/Carbopol-Based Thermosensitive Hydrogel Loaded with Ibuprofen for Potential Vaginal Drug Release.Gels (Basel, Switzerland) · 2026Article
- Gut Dysbiosis in Selected Gynecological Diseases Associated with Female Infertility: A Scoping Review.Journal of clinical medicine · 2026Review
- The Impact of the Vaginal Microbiome and Microbial Metabolites on HIV Transmission at the Female Reproductive Tract Epithelial Barrier.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026Review
- Harnessing the Vaginal Microbiome: A New Frontier in the Prevention of Sexually Transmitted Infections.Expert reviews in molecular medicine · 2026Review
- The Vaginal Microbiome and Recurrent and Chronic Urinary Tract Infection.International urogynecology journal · 2026Review
- VaginalJournal of clinical medicine · 2026Article
- Multiomic analysis reveals that polyamines alter G. vaginalis-induced cervicovaginal epithelial cell dysfunction.Research square · 2026Article
- Differential Host Gene Expression Associated with Non-Research square · 2026Article
- Protective effects ofJournal of microbiology and biotechnology · 2026Article
- Integrated cross-sectional study and functional validation indicate the association of lactobacillus crispatus-derived D-lactic acid with cervical gene expression and precancerous cervical lesions.Journal of translational medicine · 2026Article
- The Role of the Vaginal Microbiome in Gynecological Diseases: Mechanistic Insights and Emerging Interventions.Biology · 2026Review
- Vaginal-Derived Potential Probiotics and Their Postbiotics Alleviate Aerobic Vaginitis via Suppressing TLR4/MyD88/NF-κB Signalling Pathway and Potentially Enhancing Vaginal Barrier.Microbial biotechnology · 2026Article
- Vaginal microbiota in assisted reproduction: determinants, dynamics, and impact on clinical outcomes.Frontiers in microbiology · 2026Review
- The implications and mechanisms of vaginal microbiota metabolites on cervical cancer progression.Frontiers in cellular and infection microbiology · 2026Review
- Citizen science reveals comorbidities in endometriosis with no shift in vaginal microbiome composition.npj women's health · 2026Article
- Microbiome-Metabolome Crosstalk in HPV Pathogenesis: From Ecosystem Dynamics to Translational Biomarkers.Computational and structural biotechnology journal · 2026Review
- Inflammatory landscape ofFrontiers in immunology · 2026Article
- Forced vaginal sex and genital immune correlates of HIV risk: a prospective study of female sex workers in Kenya.BMJ global health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 9 institutions in 5 countries.
Funding
Abstract
Bacterial vaginosis (BV) is characterized by depletion of Lactobacillus and overgrowth of anaerobic and facultative bacteria, leading to increased mucosal inflammation, epithelial disruption, and poor reproductive health outcomes. However, the molecular mediators contributing to vaginal epithelial dysfunction are poorly understood. Here we utilize proteomic, transcriptomic, and metabolomic analyses to characterize biological features underlying BV in 405 African women and explore functional mechanisms in vitro. We identify five major vaginal microbiome groups: L. crispatus (21%), L. iners (18%), Lactobacillus (9%), Gardnerella (30%), and polymicrobial (22%). Using multi-omics we show that BV-associated epithelial disruption and mucosal inflammation link to the mammalian target of rapamycin (mTOR) pathway and associate with Gardnerella, M. mulieris, and specific metabolites including imidazole propionate. Experiments in vitro confirm that type strain G. vaginalis and M. mulieris supernatants and imidazole propionate directly affect epithelial barrier function and activation of mTOR pathways. These results find that the microbiome-mTOR axis is a central feature of epithelial dysfunction in BV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.